glofitamab (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

B-Cell Lymphoma

Pending FDA approval for relapsed/refractory large B-cell lymphoma (LBCL) after ≥2 lines of systemic therapy

Next:

Pharmacology

Mechanism of Action

Bispecific antibody designed to simultaneously bind to CD3 on T-cells and CD20 on B-cells, and induces T-cell mediated killing of CD20+ cells

CD20 is expressed on B-cells and a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.